Header image

HSANZ Free Communications 6: Low Grade Lymphoma

Tracks
HSANZ
Tuesday, November 7, 2023
8:30 AM - 10:00 AM
Meeting room 218

Speaker

Dr Arina Martynchyk
Research Fellow
Olivia Newton-John Cancer and Wellness Centre at Austin Health

Interim 3D volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary CNS lymphoma (PCNSL)

8:30 AM - 8:45 AM

Biography

A.Martynchyk worked as a Haematologist at the National Cancer Institute in Kyiv, Ukraine for the last 15 years. Currently, she is a Clinical Observer at the Department of Clinical Haematology and ONJ Cancer Centre at Austin Health and actively participates in their research activity under A/Prof E.Hawkes's supervision.
Assoc Prof Rachel Koldej
Senior Scientist
Royal Melbourne Hospital

T cell CD62L expression following nivolumab therapy is associated with long term response to rituximab-nivolumab in treatment naïve follicular lymphoma: results from the 1st FLOR study

8:45 AM - 9:00 AM

Biography

A/Prof Rachel Koldej is Senior Scientist in the ACRF Translational Research Laboratory at Royal Melbourne Hospital. Her work uses primary patient samples to understand the immunological impact of newly emerging therapies, identify treatment response biomarkers and develop novel combinations for application to the clinic.
Prof Stephen Opat
Director, Cancer Services
Monash Health / Monash University

Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial

9:00 AM - 9:15 AM

Biography

Stephen Opat is the Program Director, Cancer, at Monash Health and chairs the Lymphoma and Related Diseases Registry. He is a principal investigator in over 60 trials, mainly in lymphoid cancer and established the first-in-human haematology research unit. He has over 150 peer reviewed publications with over 8000 citations.
Prof Dipti Talaulikar
Senior Staff Specialist
Canberra Health Services

Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia

9:15 AM - 9:30 AM

Biography

Professor Dipti Talaulikar is a clinical and laboratory hematologist at Canberra Health Services and the Australian National University, having trained at Christian Medical College in Vellore India, Canberra, and ANU. She led the development of the Australian Waldenström macroglobulinemia clinical practice guidelines and has published >70 papers in the field.
Dr Bernadette De Zylva
Registrar
Northern Health

A multicentre comparative audit of Hodgkin Lymphoma patients receiving ABVD chemotherapy with or without routine GCSF prophylaxis

9:30 AM - 9:45 AM

Biography

Dr De Zylva is a basic physician trainee interested in malignant haematology. She is from the Northern Territory and is working in the haematology clinical trials unit at Northern Health.
Dr Emma Verner
Haematologist
Concord Repatriation General Hospital

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data

9:45 AM - 10:00 AM

Biography

Dr Emma Verner MBBS, BMedSci, FRCPA, FRACP is a clinical and laboratory Haematologist who joined the Concord Haematology team as a Staff Specialist in 2012. She is from Sydney originally but completed her Haematology training in Melbourne at The Austin Hospital and the Royal Melbourne Hospital.

Chairperson

Matthew Ku
Haematologist
St Vincent's Hospital

Teresa Leung
Consultant Haematologist
Northern Health

loading